Analyst Price Targets — NOV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:56 am | — | Morgan Stanley | $21.00 | $19.36 | TheFly | NOV Inc. price target raised to $21 from $20 at Morgan Stanley |
| July 8, 2026 11:55 am | — | Susquehanna | $22.00 | $18.28 | TheFly | NOV Inc. price target lowered to $22 from $24 at Susquehanna |
| June 4, 2026 12:06 pm | — | Capital One Financial | $26.00 | $21.19 | TheFly | NOV Inc. upgraded to Overweight from Equalweight at Capital One |
| June 3, 2026 10:56 pm | — | Goldman Sachs | $19.00 | $20.82 | TheFly | NOV Inc. price target lowered to $19 from $20 at Goldman Sachs |
| May 7, 2026 11:32 am | David Anderson | Barclays | $21.00 | $20.18 | TheFly | NOV Inc. downgraded to Underweight from Equal Weight at Barclays |
| April 29, 2026 11:47 am | — | Susquehanna | $24.00 | $20.29 | TheFly | NOV Inc. price target raised to $24 from $22 at Susquehanna |
| April 15, 2026 11:25 am | — | Morgan Stanley | $20.00 | $19.10 | TheFly | NOV Inc. price target raised to $20 from $18 at Morgan Stanley |
| February 9, 2026 11:57 am | Derek Podhaizer | Piper Sandler | $18.00 | $18.91 | TheFly | NOV Inc. price target raised to $18 from $17 at Piper Sandler |
| February 6, 2026 1:23 pm | Jason Bandel | Evercore ISI | $19.00 | $18.76 | TheFly | NOV Inc. price target raised to $19 from $15 at Evercore ISI |
| February 6, 2026 1:02 pm | — | Stifel Nicolaus | $21.00 | $18.78 | TheFly | NOV Inc. price target raised to $21 from $19 at Stifel |
Latest News for NOV
NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage…
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).
NOV shares rise 32% over the past six months as offshore demand, backlog growth and efficiency gains boost prospects despite tariffs and risks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.